The test identifies genetic predispositions in peptide receptor pathways (GLP1R, GIPR) and metabolic factors (FTO, MC4R) that may correlate with tolerability variation
Abbreviations ACEI: Angiotensin-converting enzyme inhibitors aHR: Adjusted hazard ratio AMI: Acute myocardial infarction ARB: Angiotensin II receptor blockers BMI: Body mass index CVD: Cardiovascular diseases CVOT: Cardiovascular outcome trial CI: Confidence interval CKD: Chronic kidney disease DM: Diabetes mellitus DPP-4i: Dipeptidyl peptidase-4 inhibitor eGFR: Estimated glomerular filtration rate ESKD: End-stage kidney disease GLP-1 RA: Glucagon-like peptide-1 receptor agonist HbA1c: Glycated hemoglobin HCOs: Healthcare organizations IQR: Interquartile range KTR: Kidney transplant recipient MACE: Major adverse cardiovascular events MAKE: Major kidney event PSM: Propensity score matching PTDM: Post-transplant diabetes mellitus RCTs: Randomized clinical trials SBP: Systolic blood pressure SD: Standard deviation SGLT2i: Sodium-glucose cotransporter 2 inhibitor SU: Sulfonylureas T2DM: Type 2 diabetes mellitus TZD: Thiazolidinediones References Rangaswami J, Mathew RO, Parasuraman R, Tantisattamo E, Lubetzky M, Rao S, Yaqub MS, Birdwell KA, Bennett W, Dalal P, et al
doi: 10.1002/dmrr.729 65 GaultVAKerrBDHarriottPFlattPR
Not appropriate for people with any of the following: Your provider will review your history and labs and discuss alternatives if semaglutide is not a fit
Fresenius Kabi AG Coherus BioSciences Inc
